Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 1475 entries
View as:

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression

Phase: N/A Priority: Normal
NCT ID: NCT00337467 Org: User:
Start: 06/30/06 End: 05/31/09 Due: 05/31/10

Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01037166 Org: User:
Start: 12/31/02 End: 02/28/05 Due: 02/28/06

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

Phase: N/A Priority: Normal
NCT ID: NCT03890770 Org: User:
Start: 04/04/19 End: 02/13/20 Due: 02/13/21

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT02319031 Org: User:
Start: 02/28/15 End: 12/31/15 Due: 12/31/16

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Phase: N/A Priority: Normal
NCT ID: NCT05489705 Org: User:
Start: 08/16/22 End: 08/17/29 Due: 08/17/30

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Phase: N/A Priority: Normal
NCT ID: NCT01455090 Org: User:
Start: 11/30/11 End: 07/31/15 Due: 07/31/16

A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06493409 Org: User:
Start: 08/26/24 End: 07/28/25 Due: 07/28/26

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01437787 Org: User:
Start: 12/31/11 End: 06/30/14 Due: 06/30/15

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Phase: N/A Priority: Normal
NCT ID: NCT05197426 Org: User:
Start: 01/17/22 End: 04/30/26 Due: 04/30/27

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT01585623 Org: User:
Start: 06/30/12 End: 03/31/13 Due: 03/31/14

Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02613507 Org: User:
Start: 12/11/15 End: 11/24/23 Due: 11/24/24

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT04623775 Org: User:
Start: 02/17/21 End: 01/30/26 Due: 01/30/27

Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01681212 Org: User:
Start: 10/31/12 End: 05/31/14 Due: 05/31/15

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

Phase: N/A Priority: Normal
NCT ID: NCT01602367 Org: User:
Start: 07/31/12 End: 11/30/12 Due: 11/30/13

DDI HV (ATV - Merck)

Phase: N/A Priority: Normal
NCT ID: NCT00518297 Org: User:
Start: 08/31/07 End: 12/31/07 Due: 12/31/08

PPAR - Combination With Metformin

Phase: N/A Priority: Normal
NCT ID: NCT00162240 Org: User:
Start: 06/30/03 End: 05/31/04 Due: 05/31/05

Abatacept With Methotrexate- Phase IIB

Phase: N/A Priority: Normal
NCT ID: NCT00162266 Org: User:
Start: 10/31/00 End: 09/30/09 Due: 09/30/10

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01968109 Org: User:
Start: 11/05/13 End: 02/03/25 Due: 02/03/26

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Phase: N/A Priority: Normal
NCT ID: NCT02856646 Org: User:
Start: 10/07/16 End: 09/30/20 Due: 09/30/21

Real-World Effectiveness of Mavacamten in Canada

Phase: N/A Priority: Normal
NCT ID: NCT06338202 Org: User:
Start: 06/26/24 End: 11/01/24 Due: 11/01/25

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

Phase: N/A Priority: Normal
NCT ID: NCT02273960 Org: User:
Start: 11/17/14 End: 01/22/18 Due: 01/22/19

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04736134 Org: User:
Start: 03/03/21 End: 03/14/24 Due: 03/14/25

Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept

Phase: N/A Priority: Normal
NCT ID: NCT01221636 Org: User:
Start: 10/31/10 End: 02/28/11 Due: 02/28/12

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01404572 Org: User:
Start: 08/31/11 End: 09/30/11 Due: 09/30/12

Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02705989 Org: User:
Start: 08/18/16 End: 08/16/17 Due: 08/16/18